Immunology

Efgartigimod (Vyvgart) — ADAPT SERON

argenx

FcRn antagonist. Approved in AChR-Ab+ gMG. ADAPT SERON Phase 3 in seronegative gMG hit primary endpoint. sBLA Priority Review; PDUFA May 10, 2026. First therapy for seronegative gMG.

Myasthenia GravisSeronegative gMG

Linked Studies

NCT06298552PrimaryACTIVE_NOT_RECRUITINGPHASE3

A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis

Generalized Myasthenia GravisgMGUpdated Nov 2025

Loading comments…

Also Known As

Other names

efgartigimod

Search all trials →Request coverage update